Breakthrough Alzheimer's trial tests multiple new therapies simultaneously
NCT ID NCT06957418
Summary
This clinical trial is testing whether new treatments that target tau protein in the brain can slow Alzheimer's disease progression. The study will enroll 900 adults aged 50-80 with early signs of Alzheimer's but minimal symptoms. Participants will receive either tau therapies alone, tau therapies combined with the approved drug donanemab, or donanemab alone for 30 months to see which approach works best.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.